Mark Thursz
Overview
Explore the profile of Mark Thursz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
131
Citations
2932
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shiffman M, Da B, Goel A, Kwong A, Stein L, Moreno C, et al.
NEJM Evid
. 2025 Jan;
4(2):EVIDoa2400243.
PMID: 39873544
Background: Larsucosterol is a DNA methyltransferase inhibitor in development for alcohol-associated hepatitis (AH), a disease for which there is no approved therapy. Methods: In this phase 2b trial, patients with...
2.
Arab J, Diaz L, Rehm J, Im G, Arrese M, Kamath P, et al.
J Hepatol
. 2024 Nov;
PMID: 39608457
In this position statement, we explore the intricate relationship between alcohol intake and metabolic dysfunction in the context of the 2023 nomenclature update for steatotic liver disease (SLD). Recent and...
3.
Ceesay A, Drammeh S, Ndow G, Jallow A, Nyang H, Bittaye B, et al.
Microorganisms
. 2024 Nov;
12(11).
PMID: 39597662
The GeneXpert HBV Viral Load test is a simplified tool to scale up screening and HBV monitoring in resource-limited settings, where HBV is endemic and where molecular techniques to quantify...
4.
Ndow G, Shimakawa Y, Leith D, Bah S, Bangura R, Mahmoud I, et al.
Lancet Gastroenterol Hepatol
. 2024 Nov;
9(12):1133-1146.
PMID: 39521002
Background: Expanding antiviral therapy to people with chronic hepatitis B virus (HBV) infection who are ineligible to receive treatment under current international criteria has been increasingly debated. Evidence to support...
5.
Vergis N, Patel V, Bogdanowicz K, Czyzewska-Khan J, Keshinro R, Fiorentino F, et al.
Clin Gastroenterol Hepatol
. 2024 Aug;
PMID: 39181422
Background And Aims: Short-term mortality in alcohol-related hepatitis (AH) is high, and no current therapy results in durable benefit. A role for interleukin (IL)-1β has been demonstrated in the pathogenesis...
6.
Lewis H, Parker R, Ul-Haq Z, Lucas A, Cohen C, Vergis N, et al.
Liver Int
. 2024 May;
44(9):2273-2281.
PMID: 38771187
Background And Aims: To examine the healthcare contacts of patients in the year before an index admission to hospital with alcohol-related liver disease (ArLD) to identify where opportunities for earlier...
7.
8.
Nguyen L, Lemoine M, Ndow G, Ward Z, Hallet T, DAlessandro U, et al.
Lancet Glob Health
. 2023 Dec;
12(1):e66-e78.
PMID: 38097300
Background: Global elimination of hepatitis B virus (HBV) requires expanded uptake of antiviral therapy, potentially by simplifying testing algorithms, especially in resource-limited countries. We evaluated the effectiveness, cost-effectiveness, and budget...
9.
Tyson L, Atkinson S, Hunter R, Thursz M, Vergis N
Aliment Pharmacol Ther
. 2023 Dec;
59(1):124-125.
PMID: 38085936
No abstract available.
10.
Thursz M, Lingford-Hughes A
BMJ
. 2023 Nov;
383:e077090.
PMID: 37984967
Alcohol-related liver disease (ALD) is a major cause of liver-related morbidity and mortality. Epidemiological trends indicate recent and predicted increases in the burden of disease. Disease progression is driven by...